Ambys Medicines develops cell therapies to treat severe liver diseases, pioneering the novel application of cell therapy approaches to restore and reverse liver disease progression. The company's lead candidate, AMI-9, is designed to address life-threatening liver conditions by leveraging cellular regenerative medicine approaches that go beyond traditional pharmaceutical treatments. Ambys focuses on developing therapies that can halt or reverse the progression of severe liver diseases where current treatment options are limited, potentially reducing the need for liver transplantation. The company combines expertise in cell biology, hepatology, and translational medicine to advance its therapeutic pipeline. Founded in 2018 and headquartered in Redwood City, California, Ambys Medicines has raised approximately $107 million in Series A funding from investors including Third Rock Ventures, Takeda, Schroders, Laurion Capital, and Alexandria.
Ambys Medicines
Series AAmbys Medicines develops cell therapies to treat severe liver diseases, pioneering the novel application of cell therapy approaches to restore and reverse liver disease progression. The company's lead candidate, AMI-9, is designed to address life-threatening liver conditions by leveraging cellular regenerative medicine approaches that go beyond traditional pharmaceutical treatments. Ambys focuses on developing…
About
Business model
Metabolic Diseases > Drugs > Hepatic disorders,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > Massachusetts Institute of Technology, Harvard University
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Backed by funds in our directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.